Robert I. Haddad, MD

Medical Oncology

Make an Appointment
Watch Video

Physician

Chief, Division of Head and Neck Oncology
Institute Physician
Professor of Medicine, Harvard Medical School

Centers/Programs

Head and Neck Cancer

Clinical Interests

Head and neck oncology

Diseases Treated

Contact Information

Appointments877-332-4294 (new)
617-632-3090 (follow-up)
Office Phone Number617-632-3090
Fax617-632-4448

Make an Appointment

Bio

Dr Haddad received his MD Degree from St. Joseph University French School of Medicine in Beirut. He completed his residency in internal medicine at St Luke's Roosevelt Medical Center in New York City, and completed a fellowship in hematology oncology at the University of Maryland Cancer Center in Baltimore.

Board Certification:

Internal Medicine, 1998
Medical Oncology, 2001

Fellowship:

University of Maryland, Baltimore, Hematology & Oncology

Residency:

Saint Luke's - Roosevelt Hospital Center, Internal Medicine

Medical School:

Saint Joseph University Medical School

Research

Clinical Investigation of Head and Neck Cancer

As the Chief of the Division of Head and Neck Oncology, I care for patients with head and neck cancer and also supervise clinical trials involving these patients. They are typically treated in a multidisciplinary clinic in close collaboration with the Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC), the Department of Radiation Oncology at DFCI, dentistry, speech and swallow therapists, and oral surgery. I also conduct translational research in cooperation with Harvard School of Public Health, Harvard School of Dental Medicine, the Forsyth Institute, the Phyllis F. Cantor Center for Research in Nursing and Patient Care Services, and other disease centers. In addition, I am responsible for teaching fellows who rotate through the Head and Neck Cancer Program, as well as medical students, medical residents, and ear, nose, and throat residents through the DF/BWCC. My current clinical research activities involve the use of an intensive chemoradiotherapy regimen for patients with locally advanced head and neck cancer, with particular attention to radioprotection and cytoprotection. We have initiated a large randomized phase II study with chemoradiotherapy and subcutaneous amifostine. This very important study, conducted across multiple sites, opened and began accruing patients in 2005. We have also started a large phase III study, called the Paradigm Trial, that compares sequential chemoradiotherapy with concomitant chemoradiotherapy. This study will enroll more than 300 patients in different institutions around the country. In other research, we are working with the National Cancer Institute/Cancer Therapy Evaluation program to develop a phase II study examining the use of depsipeptide in head and neck cancer. We will also be looking at new molecules - including Erbitux (cetuximab), lapatinib, ZD6474, and others - for the treatment of head and neck cancer.

View Dr. Haddad's Publications

Schoenfeld JD, Hanna GJ, Jo VY, Rawal B, Chen YH, Catalano PS, Lako A, Ciantra Z, Weirather JL, Criscitiello S, Luoma A, Chau N, Lorch J, Kass JI, Annino D, Goguen L, Desai A, Ross B, Shah HJ, Jacene HA, Margalit DN, Tishler RB, Wucherpfennig KW, Rodig SJ, Uppaluri R, Haddad RI. Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial. JAMA Oncol. 2020 Aug 27.
View in: PubMed

Arbab M, Chen YH, Criscitiello S, Glass J, Fugazzotto JA, Killoran JH, Hanna G, Lorch J, Haddad RI, Margalit DN, Tishler RB, Schoenfeld JD. Patient reported outcomes in patients with head and neck cancer treated with concurrent chemoradiation with weekly versus bolus cisplatin. Head Neck. 2020 Aug 19.
View in: PubMed

Mahmood U, Bang A, Chen YH, Mak RH, Lorch JH, Hanna GJ, Nishino M, Manuszak C, Thrash EM, Severgnini M, Sanborn M, Sridharan V, Margalit DN, Tishler RB, Busse PM, Willers H, Mamon HJ, Yoo HJ, Pai SI, Wirth LJ, Haddad RI, Chau NG, Schoenfeld JD. A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. Int J Radiat Oncol Biol Phys. 2020 Aug 08.
View in: PubMed

Khalaf MG, Haddad R, Akiki M, Khazen J, Melkane AE. Multifocal adult rhabdomyoma of the head and neck: case report and systematic review of the literature. Int J Oral Maxillofac Surg. 2020 Aug 06.
View in: PubMed

Uppaluri R, Campbell KM, Egloff AM, Zolkind P, Skidmore ZL, Nussenbaum B, Paniello RC, Rich JT, Jackson R, Pipkorn P, Michel LS, Ley J, Oppelt P, Dunn GP, Barnell EK, Spies NC, Lin T, Li T, Mulder DT, Hanna Y, Cirlan I, Pugh TJ, Mudianto T, Riley R, Zhou L, Jo VY, Stachler MD, Hanna GJ, Kass J, Haddad R, Schoenfeld JD, Gjini E, Lako A, Thorstad W, Gay HA, Daly M, Rodig SJ, Hagemann IS, Kallogjeri D, Piccirillo JF, Chernock RD, Griffith M, Griffith OL, Adkins DR. Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial. Clin Cancer Res. 2020 Jul 14.
View in: PubMed

Pfister DG, Spencer S, Adelstein D, Adkins D, Anzai Y, Brizel DM, Bruce JY, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Eisele DW, Fenton M, Foote RL, Galloway T, Gillison ML, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco JW, Rodriguez CP, Shah JP, Weber RS, Weinstein G, Witek M, Worden F, Yom SS, Zhen W, Burns JL, Darlow SD. Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 Jul; 18(7):873-898.
View in: PubMed

Kreissl MC, Bastholt L, Elisei R, Haddad R, Hauch O, Jarzab B, Robinson B, Colzani R, Foster M, Weiss R, Schlumberger M. Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial. J Clin Oncol. 2020 Aug 20; 38(24):2773-2781.
View in: PubMed

Schoenfeld JD, Fell G, Haddad RI, Trippa L. Keynote 48: Is it really for everyone? Oral Oncol. 2020 06; 105:104762.
View in: PubMed

Abou Alaiwi S, Nassar AH, Xie W, Bakouny Z, Berchuck JE, Braun DA, Baca SC, Nuzzo PV, Flippot R, Mouhieddine TH, Spurr LF, Li YY, Li T, Flaifel A, Steinharter JA, Margolis CA, Vokes NI, Du H, Shukla SA, Cherniack AD, Sonpavde G, Haddad RI, Awad MM, Giannakis M, Hodi FS, Liu XS, Signoretti S, Kadoch C, Freedman ML, Kwiatkowski DJ, Van Allen EM, Choueiri TK. Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. Cancer Immunol Res. 2020 Aug; 8(8):1075-1084.
View in: PubMed

Hanna GJ, Bae JE, Lorch JH, Haddad RI, Jo VY, Schoenfeld JD, Margalit DN, Tishler RB, Goguen LA, Annino DJ, Chau NG. The Benefits of Adjuvant Trastuzumab for HER-2-Positive Salivary Gland Cancers. Oncologist. 2020 Jul; 25(7):598-608.
View in: PubMed

Ferris RL, Haddad R, Even C, Tahara M, Dvorkin M, Ciuleanu TE, Clement PM, Mesia R, Kutukova S, Zholudeva L, Daste A, Caballero-Daroqui J, Keam B, Vynnychenko I, Lafond C, Shetty J, Mann H, Fan J, Wildsmith S, Morsli N, Fayette J, Licitra L. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. Ann Oncol. 2020 Jul; 31(7):942-950.
View in: PubMed

Hanna GJ, Bae JE, Lorch JH, Schoenfeld JD, Margalit DN, Tishler RB, Haddad RI, Chau NG. Long-term outcomes and clinicogenomic correlates in recurrent, metastatic adenoid cystic carcinoma. Oral Oncol. 2020 07; 106:104690.
View in: PubMed

Kacew AJ, Harris EJ, Lorch JH, Schoenfeld JD, Margalit DN, Kass JI, Tishler RB, Haddad RI, Hanna GJ. Chemotherapy after immune checkpoint blockade in patients with recurrent, metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2020 06; 105:104676.
View in: PubMed

Haddad R, Cohen EEW, Venkatachalam M, Young K, Singh P, Shaw JW, Korytowsky B, Abraham P, Harrington KJ. Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States. J Med Econ. 2020 May; 23(5):442-447.
View in: PubMed

Shazib MA, Woo SB, Sroussi H, Carvo I, Treister N, Farag A, Schoenfeld J, Haddad R, LeBoeuf N, Villa A. Oral immune-related adverse events associated with PD-1 inhibitor therapy: A case series. Oral Dis. 2020 Mar; 26(2):325-333.
View in: PubMed

Sher DJ, Thotakura V, Balboni TA, Norris CM, Haddad RI, Posner MR, Lorch J, Goguen LA, Annino DJ, Tishler RB. Treatment of oropharyngeal squamous cell carcinoma with IMRT: patterns of failure after concurrent chemoradiotherapy and sequential therapy. Ann Oncol. 2012 Sep; 23(9):2391-2398.
View in: PubMed

Chau NG, Ma C, Danga K, Al-Sayegh H, Nardi V, Barrette R, Lathan CS, DuBois SG, Haddad RI, Shapiro GI, Sallan SE, Dhar A, Nelson JJ, French CA. An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 Patients. JNCI Cancer Spectr. 2020 Apr; 4(2):pkz094.
View in: PubMed

Mesia R, Bossi P, Hansen AR, Hsieh CY, Licitra LF, Tan EH, Chen P, Miller J, Siu LL, Haddad RI. Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma. Eur J Cancer. 2019 12; 123:138-145.
View in: PubMed

Robert H, Pichon B, Haddad R. [Sexual dysfunctions after traumatic brain injury: Systematic review of the literature]. Prog Urol. 2019 Sep; 29(11):529-543.
View in: PubMed

Oosting SF, Haddad RI. Best Practice in Systemic Therapy for Head and Neck Squamous Cell Carcinoma. Front Oncol. 2019; 9:815.
View in: PubMed

Haddad R, Guigay J, Keilholz U, Clement PM, Fayette J, de Souza Viana L, Rolland F, Cupissol D, Geoffrois L, Kornek G, Licitra L, Melichar B, Ribaldo Nicolau U, Rauch D, Zanetta-Devauges S, Cohen EEW, Machiels JP, Tahara M, Vermorken J, Geng Y, Zografos E, Gauler T. Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial. Oral Oncol. 2019 10; 97:82-91.
View in: PubMed

D'Souza G, Clemens G, Troy T, Castillo RG, Struijk L, Waterboer T, Bender N, Pierorazio PM, Best SR, Strickler H, Wiley DJ, Haddad RI, Posner M, Fakhry C. Evaluating the Utility and Prevalence of HPV Biomarkers in Oral Rinses and Serology for HPV-related Oropharyngeal Cancer. Cancer Prev Res (Phila). 2019 10; 12(10):689-700.
View in: PubMed

Mahal BA, Catalano PJ, Haddad RI, Hanna GJ, Kass JI, Schoenfeld JD, Tishler RB, Margalit DN. Incidence and Demographic Burden of HPV-Associated Oropharyngeal Head and Neck Cancers in the United States. Cancer Epidemiol Biomarkers Prev. 2019 10; 28(10):1660-1667.
View in: PubMed

Haddad R, Concha-Benavente F, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Kasper S, Vokes EE, Worden F, Saba NF, Tahara M, Jayaprakash V, Lynch M, Li L, Gillison ML, Harrington KJ, Ferris RL. Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial. Cancer. 2019 09 15; 125(18):3208-3218.
View in: PubMed

Ferris RL, Licitra L, Fayette J, Even C, Blumenschein G, Harrington KJ, Guigay J, Vokes EE, Saba NF, Haddad R, Ramkumar S, Russell J, Brossart P, Tahara M, Colevas AD, Concha-Benavente F, Lynch M, Li L, Gillison ML. Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. Clin Cancer Res. 2019 09 01; 25(17):5221-5230.
View in: PubMed

Hanna GJ, Lau CJ, Mahmood U, Supplee JG, Mogili AR, Haddad RI, Jänne PA, Paweletz CP. Salivary HPV DNA informs locoregional disease status in advanced HPV-associated oropharyngeal cancer. Oral Oncol. 2019 08; 95:120-126.
View in: PubMed

Burtness B, Haddad R, Dinis J, Trigo J, Yokota T, de Souza Viana L, Romanov I, Vermorken J, Bourhis J, Tahara M, Martins Segalla JG, Psyrri A, Vasilevskaya I, Nangia CS, Chaves-Conde M, Kiyota N, Homma A, Holeckova P, Del Campo JM, Asarawala N, Nicolau UR, Rauch D, Even C, Wang B, Gibson N, Ehrnrooth E, Harrington K, Cohen EEW. Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial. JAMA Oncol. 2019 Jun 13.
View in: PubMed

Margalit DN, Haddad RI, Tishler RB, Chau NG, Schoenfeld JD, Bakst RL, Misiukiewicz KJ, Gupta V, Posner M, Hanna GJ, Mahmood U, Rawal B, Catalano PJ, Rath L, Bacay A, McHugh P, Rabinowits G. A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy with and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck. Int J Radiat Oncol Biol Phys. 2019 09 01; 105(1):132-139.
View in: PubMed

Kacew AJ, Harris EJ, Lorch JH, Haddad RI, Chau NG, Rabinowits G, LeBoeuf NR, Schmults CD, Thakuria M, MacConaill LE, Hanna GJ. Chromosome 3q arm gain linked to immunotherapy response in advanced cutaneous squamous cell carcinoma. Eur J Cancer. 2019 05; 113:1-9.
View in: PubMed

Haddad RI, Massarelli E, Lee JJ, Lin HY, Hutcheson K, Lewis J, Garden AS, Blumenschein GR, William WN, Pharaon RR, Tishler RB, Glisson BS, Pickering C, Gold KA, Johnson FM, Rabinowits G, Ginsberg LE, Williams MD, Myers J, Kies MS, Papadimitrakopoulou V. Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma. Ann Oncol. 2019 03 01; 30(3):471-477.
View in: PubMed

Harris EJ, Hanna GJ, Chau N, Rabinowits G, Haddad R, Margalit DN, Schoenfeld J, Tishler RB, Barletta JA, Nehs M, Janne P, Huang J, Groden P, Kacew A, Lorch J. Everolimus in Anaplastic Thyroid Cancer: A Case Series. Front Oncol. 2019; 9:106.
View in: PubMed

LaVigne AW, Margalit DN, Rawal B, Puzanov M, Annino DJ, Goguen LA, Sher DJ, Schoenfeld JD, Chau NG, Lorch JH, Rabinowits G, Haddad RI, Tishler RB. IMRT-based treatment of unknown primary malignancy of the head and neck: Outcomes and improved toxicity with decreased mucosal dose and larynx sparing. Head Neck. 2019 04; 41(4):959-966.
View in: PubMed

Biardeau X, Haddad R, Chesnel C, Charlanes A, Hentzen C, Turmel N, Campagne S, Capon G, Fatton B, Gamé X, Jeandel C, Kerdraon J, Mares P, Mezzadri M, Petit AC, Peyronnet B, Soler JM, Thuillier C, Deffieux X, Robain G, Amarenco G, Manceau P. [Use of botulinum toxin A in pelvic floor dysfunctions in the elderly: A review]. Prog Urol. 2019 Mar; 29(4):216-225.
View in: PubMed

Haddad RI, Nasr C, Bischoff L, Busaidy NL, Byrd D, Callender G, Dickson P, Duh QY, Ehya H, Goldner W, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, McIver B, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Sippel R, Smallridge RC, Sturgeon C, Wang TN, Wirth LJ, Wong RJ, Johnson-Chilla A, Hoffmann KG, Gurski LA. NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018. J Natl Compr Canc Netw. 2018 12; 16(12):1429-1440.
View in: PubMed

Ferris RL, Saba NF, Gitlitz BJ, Haddad R, Sukari A, Neupane P, Morris JC, Misiukiewicz K, Bauman JE, Fenton M, Jimeno A, Adkins DR, Schneider CJ, Sacco AG, Shirai K, Bowles DW, Gibson M, Nwizu T, Gottardo R, Manjarrez KL, Dietsch GN, Bryan JK, Hershberg RM, Cohen EEW. Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial. JAMA Oncol. 2018 11 01; 4(11):1583-1588.
View in: PubMed

Tsai FD, Haddad RI. Toward a Personalized Approach in the Treatment of Salivary Ductal Carcinoma. J Natl Compr Canc Netw. 2018 10; 16(10):1269-1270.
View in: PubMed

Hanna GJ, Kacew A, Chau NG, Shivdasani P, Lorch JH, Uppaluri R, Haddad RI, MacConaill LE. Improved outcomes in PI3K-pathway-altered metastatic HPV oropharyngeal cancer. JCI Insight. 2018 09 06; 3(17).
View in: PubMed

Hanna GJ, Supplee JG, Kuang Y, Mahmood U, Lau CJ, Haddad RI, Jänne PA, Paweletz CP. Plasma HPV cell-free DNA monitoring in advanced HPV-associated oropharyngeal cancer. Ann Oncol. 2018 09 01; 29(9):1980-1986.
View in: PubMed

Miao D, Margolis CA, Vokes NI, Liu D, Taylor-Weiner A, Wankowicz SM, Adeegbe D, Keliher D, Schilling B, Tracy A, Manos M, Chau NG, Hanna GJ, Polak P, Rodig SJ, Signoretti S, Sholl LM, Engelman JA, Getz G, Jänne PA, Haddad RI, Choueiri TK, Barbie DA, Haq R, Awad MM, Schadendorf D, Hodi FS, Bellmunt J, Wong KK, Hammerman P, Van Allen EM. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat Genet. 2018 09; 50(9):1271-1281.
View in: PubMed

Sridharan V, Rahman RM, Huang RY, Chau NG, Lorch JH, Uppaluri R, Haddad RI, Hanna GJ, Schoenfeld JD. Radiologic predictors of immune checkpoint inhibitor response in advanced head and neck squamous cell carcinoma. Oral Oncol. 2018 10; 85:29-34.
View in: PubMed

Schoenfeld JD, Gjini E, Rodig SJ, Tishler RB, Rawal B, Catalano PJ, Uppaluri R, Haddad RI, Hanna GJ, Chau NG, Rabinowits G, Lorch J, Jo VY, Krane JF, Goguen LA, Annino DJ, Abdelrahman S, Lipschitz M, Margalit DN. Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2018 09 01; 102(1):137-145.
View in: PubMed

Mehra R, Seiwert TY, Gupta S, Weiss J, Gluck I, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Geva R, Chung HC, Lin CC, Aurora-Garg D, Ray A, Pathiraja K, Cheng J, Chow LQM, Haddad R. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br J Cancer. 2018 07; 119(2):153-159.
View in: PubMed

Gillison ML, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Li L, Ferris RL. CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. Oncologist. 2018 09; 23(9):1079-1082.
View in: PubMed

Ferrarotto R, William WN, Tseng JE, Marur S, Shin DM, Murphy B, Cohen EEW, Thomas CY, Willey R, Cosaert J, Harun N, Jack Lee J, Wistuba IW, Haddad RI, Glisson BS. Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncol. 2018 07; 82:83-90.
View in: PubMed

Colevas AD, Yom SS, Pfister DG, Spencer S, Adelstein D, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Eisele DW, Fenton M, Foote RL, Gilbert J, Gillison ML, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Zhen W, Burns JL, Darlow SD. NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018. J Natl Compr Canc Netw. 2018 05; 16(5):479-490.
View in: PubMed

Haddad RI, Posner M, Hitt R, Cohen EEW, Schulten J, Lefebvre JL, Vermorken JB. Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions. Ann Oncol. 2018 05 01; 29(5):1130-1140.
View in: PubMed

Brose MS, Bible KC, Chow LQM, Gilbert J, Grande C, Worden F, Haddad R. Management of treatment-related toxicities in advanced medullary thyroid cancer. Cancer Treat Rev. 2018 May; 66:64-73.
View in: PubMed

Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison ML. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol. 2018 06; 81:45-51.
View in: PubMed

Chesnel C, Charlanes A, Hentzen C, Turmel N, Biardeau X, Brochard C, Campagne S, Capon G, Deffieux X, Fatton B, Gamé X, Haddad R, Jeandel C, Kerdraon J, Manceau P, Mares P, Mezzadri M, Mongiat-Artus P, Petit AC, Peyronnet B, Soler JM, Thuillier C, Vetel JM, Robain G, Amarenco G. [Cardiovascular adverse effects of antimuscarinics used in the treatment of overactive bladder in the elderly : A review]. Prog Urol. 2018 Jun; 28(7):361-369.
View in: PubMed

Hanna GJ, Kofman ER, Shazib MA, Woo SB, Reardon B, Treister NS, Haddad RI, Cutler CS, Antin JH, Van Allen EM, Uppaluri R, Soiffer RJ. Integrated genomic characterization of oral carcinomas in post-hematopoietic stem cell transplantation survivors. Oral Oncol. 2018 06; 81:1-9.
View in: PubMed

Hanna GJ, Lizotte P, Cavanaugh M, Kuo FC, Shivdasani P, Frieden A, Chau NG, Schoenfeld JD, Lorch JH, Uppaluri R, MacConaill LE, Haddad RI. Frameshift events predict anti-PD-1/L1 response in head and neck cancer. JCI Insight. 2018 02 22; 3(4).
View in: PubMed

Rabinowits G, Lezcano C, Catalano PJ, McHugh P, Becker H, Reilly MM, Huang J, Tyagi A, Thakuria M, Bresler SC, Sholl LM, Shapiro GI, Haddad R, DeCaprio JA. Cabozantinib in Patients with Advanced Merkel Cell Carcinoma. Oncologist. 2018 07; 23(7):814-821.
View in: PubMed

Hanna GJ, Busaidy NL, Chau NG, Wirth LJ, Barletta JA, Calles A, Haddad RI, Kraft S, Cabanillas ME, Rabinowits G, O'Neill A, Limaye SA, Alexander EK, Moore FD, Misiwkeiwicz K, Thomas T, Nehs M, Marqusee E, Lee SL, Jänne PA, Lorch JH. Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study. Clin Cancer Res. 2018 04 01; 24(7):1546-1553.
View in: PubMed

Sultan A, Hanna GJ, Margalit DN, Chau N, Goguen LA, Marty FM, Rabinowits G, Schoenfeld JD, Sonis ST, Thomas T, Tishler RB, Treister NS, Villa A, Woo SB, Haddad R, Mawardi H. The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline. Oncologist. 2017 11; 22(11):1413.
View in: PubMed

Cohen EEW, Licitra LF, Burtness B, Fayette J, Gauler T, Clement PM, Grau JJ, Del Campo JM, Mailliez A, Haddad RI, Vermorken JB, Tahara M, Guigay J, Geoffrois L, Merlano MC, Dupuis N, Krämer N, Cong XJ, Gibson N, Solca F, Ehrnrooth E, Machiels JH. Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer. Ann Oncol. 2017 Oct 01; 28(10):2526-2532.
View in: PubMed

Margalit DN, Schoenfeld JD, Rawal B, Haddad RI, Catalano PJ, Goguen LA, Chau NG, Rabinowits G, Lorch JH, Annino DJ, Tishler RB. Patient-oriented toxicity endpoints after head and neck reirradiation with intensity modulated radiation therapy. Oral Oncol. 2017 10; 73:160-165.
View in: PubMed

Rabinowits G, Bowden M, Flores LM, Verselis S, Vergara V, Jo VY, Chau N, Lorch J, Hammerman PS, Thomas T, Goguen LA, Annino D, Schoenfeld JD, Margalit DN, Tishler RB, Haddad RI. Comparative Analysis of MicroRNA Expression among Benign and Malignant Tongue Tissue and Plasma of Patients with Tongue Cancer. Front Oncol. 2017; 7:191.
View in: PubMed

Harrington KJ, Ferris RL, Blumenschein G, Colevas AD, Fayette J, Licitra L, Kasper S, Even C, Vokes EE, Worden F, Saba NF, Kiyota N, Haddad R, Tahara M, Grünwald V, Shaw JW, Monga M, Lynch M, Taylor F, DeRosa M, Morrissey L, Cocks K, Gillison ML, Guigay J. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol. 2017 08; 18(8):1104-1115.
View in: PubMed

Adelstein D, Gillison ML, Pfister DG, Spencer S, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Eisele DW, Fenton M, Foote RL, Gilbert J, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Lydiatt WM, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Yom SS, Zhen W, Burns JL, Darlow SD. NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017. J Natl Compr Canc Netw. 2017 06; 15(6):761-770.
View in: PubMed

Porceddu SV, Haddad RI. Management of elderly patients with locoregionally confined head and neck cancer. Lancet Oncol. 2017 05; 18(5):e274-e283.
View in: PubMed

Bignami B, Honore T, Turmel N, Haddad R, Weglinski L, Le Breton F, Amarenco G. [Post-orgasmic illness syndrome]. Prog Urol. 2017 Jun; 27(7):446-448.
View in: PubMed

Chau NG, Tishler RB, Haddad RI. Highlights in Head and Neck Cancer. JAMA Oncol. 2017 04 01; 3(4):441-442.
View in: PubMed

Haddad R, Glass J. Advances in Collaborative Practice for Patients With Head and Neck Cancers. J Adv Pract Oncol. 2017 Apr; 8(3):261-265.
View in: PubMed

Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, Saba NF, Weiss J, Wirth L, Sukari A, Kang H, Gibson MK, Massarelli E, Powell S, Meister A, Shu X, Cheng JD, Haddad R. Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. J Clin Oncol. 2017 May 10; 35(14):1542-1549.
View in: PubMed

Sultan A, Hanna GJ, Margalit DN, Chau N, Goguen LA, Marty FM, Rabinowits G, Schoenfeld JD, Sonis ST, Thomas T, Tishler RB, Treister NS, Villa A, Woo SB, Haddad R, Mawardi H. The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline. Oncologist. 2017 03; 22(3):343-350.
View in: PubMed

Zhang Y, Waterboer T, Haddad RI, Miles BA, Wentz A, Gross ND, Fakhry C, Quon H, Lorch JH, Gourin CG, Clayburgh D, Misiukiewicz KJ, Richmon JD, Andersen PE, Posner MR, D'Souza G. Human papillomavirus (HPV) 16 antibodies at diagnosis of HPV-related oropharyngeal cancer and antibody trajectories after treatment. Oral Oncol. 2017 04; 67:77-82.
View in: PubMed

Hanna GJ, Liu H, Jones RE, Bacay AF, Lizotte PH, Ivanova EV, Bittinger MA, Cavanaugh ME, Rode AJ, Schoenfeld JD, Chau NG, Haddad RI, Lorch JH, Wong KK, Uppaluri R, Hammerman PS. Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2017 04; 67:61-69.
View in: PubMed

Haddad RI, Schlumberger M, Wirth LJ, Sherman EJ, Shah MH, Robinson B, Dutcus CE, Teng A, Gianoukakis AG, Sherman SI. Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes. Endocrine. 2017 Apr; 56(1):121-128.
View in: PubMed

Hanna GJ, Sridharan V, Margalit DN, La Follette SK, Chau NG, Rabinowits G, Lorch JH, Haddad RI, Tishler RB, Anderson KS, Schoenfeld JD. Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma. Cancer Biomark. 2017; 19(2):129-136.
View in: PubMed

Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016 11 10; 375(19):1856-1867.
View in: PubMed

Chow LQM, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee SH, Keam B, Kang H, Muro K, Weiss J, Geva R, Lin CC, Chung HC, Meister A, Dolled-Filhart M, Pathiraja K, Cheng JD, Seiwert TY. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. J Clin Oncol. 2016 11 10; 34(32):3838-3845.
View in: PubMed

Chau NG, Haddad RI. Antiangiogenic agents in head and neck squamous cell carcinoma: Tired of going solo. Cancer. 2016 12 01; 122(23):3592-3595.
View in: PubMed

Lu W, Wayne PM, Davis RB, Buring JE, Li H, Macklin EA, Lorch JH, Burke E, Haddad TC, Goguen LA, Rosenthal DS, Tishler RB, Posner MR, Haddad RI. Acupuncture for Chemoradiation Therapy-Related Dysphagia in Head and Neck Cancer: A Pilot Randomized Sham-Controlled Trial. Oncologist. 2016 12; 21(12):1522-1529.
View in: PubMed

Chau NG, Hurwitz S, Mitchell CM, Aserlind A, Grunfeld N, Kaplan L, Hsi P, Bauer DE, Lathan CS, Rodriguez-Galindo C, Tishler RB, Haddad RI, Sallan SE, Bradner JE, French CA. Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck. Cancer. 2016 Dec 01; 122(23):3632-3640.
View in: PubMed

Margalit DN, Rawal B, Catalano PJ, Haddad RI, Goguen LA, Annino DJ, Limaye SA, Lorch JH, Lavigne AW, Schoenfeld JD, Sher DJ, Tishler RB. Patterns of failure after reirradiation with intensity-modulated radiation therapy and the competing risk of out-of-field recurrences. Oral Oncol. 2016 10; 61:19-26.
View in: PubMed

Sridharan V, Margalit DN, Lynch SA, Severgnini M, Zhou J, Chau NG, Rabinowits G, Lorch JH, Hammerman PS, Hodi FS, Haddad RI, Tishler RB, Schoenfeld JD. Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. Br J Cancer. 2016 07 12; 115(2):252-60.
View in: PubMed

Boffetta P, Hayes RB, Sartori S, Lee YC, Muscat J, Olshan A, Winn DM, Castellsagué X, Zhang ZF, Morgenstern H, Chen C, Schwartz SM, Vaughan TL, Wunsch-Filho V, Purdue M, Koifman S, Curado MP, Vilensky M, Gillison M, Fernandez L, Menezes A, Daudt AW, Schantz S, Yu G, D'Souza G, Haddad RI, La Vecchia C, Hashibe M. Mouthwash use and cancer of the head and neck: a pooled analysis from the International Head and Neck Cancer Epidemiology Consortium. Eur J Cancer Prev. 2016 07; 25(4):344-8.
View in: PubMed

Sridharan V, Margalit DN, Lynch SA, Severgnini M, Hodi FS, Haddad RI, Tishler RB, Schoenfeld JD. Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients. J Immunother Cancer. 2016; 4:32.
View in: PubMed

Sridharan V, Gjini E, Liao X, Chau NG, Haddad RI, Severgnini M, Hammerman P, El-Naggar A, Freeman GJ, Hodi FS, Rodig SJ, Dranoff G, Schoenfeld JD. Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes. Cancer Immunol Res. 2016 08; 4(8):679-87.
View in: PubMed

Hashim D, Sartori S, Brennan P, Curado MP, Wünsch-Filho V, Divaris K, Olshan AF, Zevallos JP, Winn DM, Franceschi S, Castellsagué X, Lissowska J, Rudnai P, Matsuo K, Morgenstern H, Chen C, Vaughan TL, Hofmann JN, D'Souza G, Haddad RI, Wu H, Lee YC, Hashibe M, Vecchia CL, Boffetta P. The role of oral hygiene in head and neck cancer: results from International Head and Neck Cancer Epidemiology (INHANCE) consortium. Ann Oncol. 2016 08; 27(8):1619-25.
View in: PubMed

Keane FK, Chen YH, Tishler RB, Schoenfeld JD, Haddad RI, Goguen LA, Catalano P, Neville BA, Margalit DN. Population-based validation of the recursive partitioning analysis-based staging system for oropharyngeal cancer. Head Neck. 2016 10; 38(10):1530-8.
View in: PubMed

Clement PM, Gauler T, Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Cohen EE, Cupissol D, Grau JJ, Guigay J, Caponigro F, de Castro G, de Souza Viana L, Keilholz U, Del Campo JM, Cong XJ, Ehrnrooth E, Vermorken JB. Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial. Ann Oncol. 2016 08; 27(8):1585-93.
View in: PubMed

Chau NG, Li YY, Jo VY, Rabinowits G, Lorch JH, Tishler RB, Margalit DN, Schoenfeld JD, Annino DJ, Goguen LA, Thomas T, Becker H, Haddad T, Krane JF, Lindeman NI, Shapiro GI, Haddad RI, Hammerman PS. Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2016 06 15; 22(12):2939-49.
View in: PubMed

Lorch JH, Hanna GJ, Posner MR, O'Neill A, Thotakura VL, Limaye SA, Rabinowits G, Sher DJ, Tishler RB, Haddad RI. Human papillomavirus and induction chemotherapy versus concurrent chemoradiotherapy in locally advanced oropharyngeal cancer: The Dana Farber Experience. Head Neck. 2016 04; 38 Suppl 1:E1618-24.
View in: PubMed

Hoppmann RA, Rao VV, Bell F, Poston MB, Howe DB, Riffle S, Harris S, Riley R, McMahon C, Wilson LB, Blanck E, Richeson NA, Thomas LK, Hartman C, Neuffer FH, Keisler BD, Sims KM, Garber MD, Shuler CO, Blaivas M, Chillag SA, Wagner M, Barron K, Davis D, Wells JR, Kenney DJ, Hall JW, Bornemann PH, Schrift D, Hunt PS, Owens WB, Smith RS, Jackson AG, Hagon K, Wilson SP, Fowler SD, Catroppo JF, Rizvi AA, Powell CK, Cook T, Brown E, Navarro FA, Thornhill J, Burgis J, Jennings WR, McCallum JB, Nottingham JM, Kreiner J, Haddad R, Augustine JR, Pedigo NW, Catalana PV. The evolution of an integrated ultrasound curriculum (iUSC) for medical students: 9-year experience. Crit Ultrasound J. 2015 Dec; 7(1):18.
View in: PubMed

Chau NG, Haddad RI. Sequential and Concurrent Chemoradiation: State of the Art. Hematol Oncol Clin North Am. 2015 Dec; 29(6):1061-74.
View in: PubMed

Rettig EM, Wentz A, Posner MR, Gross ND, Haddad RI, Gillison ML, Fakhry C, Quon H, Sikora AG, Stott WJ, Lorch JH, Gourin CG, Guo Y, Xiao W, Miles BA, Richmon JD, Andersen PE, Misiukiewicz KJ, Chung CH, Gerber JE, Rajan SD, D'Souza G. Prognostic Implication of Persistent Human Papillomavirus Type 16 DNA Detection in Oral Rinses for Human Papillomavirus-Related Oropharyngeal Carcinoma. JAMA Oncol. 2015 Oct; 1(7):907-15.
View in: PubMed

Ma L, Donohue C, DeNofrio T, Vitale Pedulla L, Haddad RI, Rabinowits G. Optimizing Tobacco Cessation Resource Awareness Among Patients and Providers. J Oncol Pract. 2016 Jan; 12(1):e77-82.
View in: PubMed

Haddad RI, Lydiatt WM, Ball DW, Busaidy NL, Byrd D, Callender G, Dickson P, Duh QY, Ehya H, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, McCaffrey JC, Moley JF, Parks L, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Smallridge RC, Sturgeon C, Wang TN, Wirth LJ, Hoffmann KG, Hughes M. Anaplastic Thyroid Carcinoma, Version 2.2015. J Natl Compr Canc Netw. 2015 Sep; 13(9):1140-50.
View in: PubMed

Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Foote RL, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Jimeno A, Kies MS, Lydiatt WM, Maghami E, McCaffrey T, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rodriguez CP, Samant S, Shah JP, Weber RS, Wolf GT, Worden F, Yom SS, McMillian N, Hughes M. Head and Neck Cancers, Version 1.2015. J Natl Compr Canc Netw. 2015 Jul; 13(7):847-55; quiz 856.
View in: PubMed

Haddad RI, Gupta S, Mehra R, Tahara M, Berger R, Lee SH, Burtness B, Le DT, Heath K, Blum A, Dolled-Filhart M, Emancipator K, Pathiraja K, Cheng JD, Chow LQ. Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort. J Clin Oncol. 2015 Jun 20; 33(18_suppl):LBA6008.
View in: PubMed

Anderson KS, Gerber JE, D'Souza G, Pai SI, Cheng JN, Alam R, Kesiraju S, Chowell D, Gross ND, Haddad R, Gillison ML, Posner M. Biologic predictors of serologic responses to HPV in oropharyngeal cancer: The HOTSPOT study. Oral Oncol. 2015 Aug; 51(8):751-8.
View in: PubMed

Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Vermorken JB, Clement PM, Gauler T, Cupissol D, Grau JJ, Guigay J, Caponigro F, de Castro G, de Souza Viana L, Keilholz U, Del Campo JM, Cong XJ, Ehrnrooth E, Cohen EE. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol. 2015 May; 16(5):583-94.
View in: PubMed

Margalit DN, Losi SM, Tishler RB, Schoenfeld JD, Ann Fugazzotto J, Stephens J, Cebulski AL, Hammerstrand EL, Ma L, Lopes HM, Haddad RI, Treister NS, Frustino JL. Ensuring head and neck oncology patients receive recommended pretreatment dental evaluations. J Oncol Pract. 2015 Mar; 11(2):151-4.
View in: PubMed

Li YY, Hanna GJ, Laga AC, Haddad RI, Lorch JH, Hammerman PS. Genomic analysis of metastatic cutaneous squamous cell carcinoma. Clin Cancer Res. 2015 Mar 15; 21(6):1447-56.
View in: PubMed

Haddad RI, Chan AT, Vermorken JB. Barriers to clinical trial recruitment in head and neck cancer. Oral Oncol. 2015 Mar; 51(3):203-11.
View in: PubMed

Inverso G, Mahal BA, Aizer AA, Donoff RB, Chau NG, Haddad RI. Marital status and head and neck cancer outcomes. Cancer. 2015 Apr 15; 121(8):1273-8.
View in: PubMed

Tuttle RM, Haddad RI, Ball DW, Byrd D, Dickson P, Duh QY, Ehya H, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, Lydiatt WM, McCaffrey J, Moley JF, Parks L, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ, Hoffmann KG, Hughes M. Thyroid carcinoma, version 2.2014. J Natl Compr Canc Netw. 2014 Dec; 12(12):1671-80; quiz 1680.
View in: PubMed

Chau NG, Rabinowits G, Haddad RI. Human papillomavirus-associated oropharynx cancer (HPV-OPC): treatment options. Curr Treat Options Oncol. 2014 Dec; 15(4):595-610.
View in: PubMed

Losi S, Tishler RB, Schoenfeld JD, Fugazzotto J, Stephens J, Cebulski A, Hammerstrand E, Ma L, Lopes H, Haddad RI, Treister NS, Frustino JL. Ensuring head and neck oncology patients receive recommended pretreatment dental evaluations. J Clin Oncol. 2014 Oct 20; 32(30_suppl):100.
View in: PubMed

Donohue CC, Denofrio T, Pedulla LV, Haddad RI, Jacobson JO, Rabinowits G. Optimizing smoking cessation resource awareness among patients and providers. J Clin Oncol. 2014 Oct 20; 32(30_suppl):85.
View in: PubMed

Parfenov M, Pedamallu CS, Gehlenborg N, Freeman SS, Danilova L, Bristow CA, Lee S, Hadjipanayis AG, Ivanova EV, Wilkerson MD, Protopopov A, Yang L, Seth S, Song X, Tang J, Ren X, Zhang J, Pantazi A, Santoso N, Xu AW, Mahadeshwar H, Wheeler DA, Haddad RI, Jung J, Ojesina AI, Issaeva N, Yarbrough WG, Hayes DN, Grandis JR, El-Naggar AK, Meyerson M, Park PJ, Chin L, Seidman JG, Hammerman PS, Kucherlapati R. Characterization of HPV and host genome interactions in primary head and neck cancers. Proc Natl Acad Sci U S A. 2014 Oct 28; 111(43):15544-9.
View in: PubMed

Wagle N, Grabiner BC, Van Allen EM, Amin-Mansour A, Taylor-Weiner A, Rosenberg M, Gray N, Barletta JA, Guo Y, Swanson SJ, Ruan DT, Hanna GJ, Haddad RI, Getz G, Kwiatkowski DJ, Carter SL, Sabatini DM, Jänne PA, Garraway LA, Lorch JH. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med. 2014 Oct 09; 371(15):1426-33.
View in: PubMed

Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Jimeno A, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rodriguez CP, Samant S, Schuller DE, Shah JP, Weber RS, Wolf GT, Worden F, Yom SS, McMillian NR, Hughes M. Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2014 Oct; 12(10):1454-87.
View in: PubMed

Levy J, Le Breton F, Jousse M, Haddad R, Verollet D, Guinet-Lacoste A, Amarenco G. [Bacterial ecology and resistance to antibiotics in patients with neurogenic overactive bladder treated with intravesical botulinum toxin injections]. Prog Urol. 2014 Oct; 24(12):744-9.
View in: PubMed

Haddad R, Sherman SI, Shah JP, Wirth LJ. New frontiers and treatment paradigms for thyroid carcinoma. Clin Adv Hematol Oncol. 2014 Jul; 12(7 Suppl 14):3-21; quiz 22.
View in: PubMed

Machiels JP, Licitra LF, Haddad RI, Tahara M, Cohen EE. Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy. BMC Cancer. 2014 Jun 28; 14:473.
View in: PubMed

D'Souza G, Gross ND, Pai SI, Haddad R, Anderson KS, Rajan S, Gerber J, Gillison ML, Posner MR. Oral human papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners. J Clin Oncol. 2014 Aug 10; 32(23):2408-15.
View in: PubMed

Hanna JW, Reimann JD, Haddad RI, Krane JF. Human papillomavirus-associated adenocarcinoma of the palatine tonsil--reply. Hum Pathol. 2014 Apr; 45(4):895.
View in: PubMed

Limaye SA, Haddad RI, Cilli F, Sonis ST, Colevas AD, Brennan MT, Hu KS, Murphy BA. Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy. Cancer. 2013 Dec 15; 119(24):4268-76.
View in: PubMed

Schmitz S, Ang KK, Vermorken J, Haddad R, Suarez C, Wolf GT, Hamoir M, Machiels JP. Targeted therapies for squamous cell carcinoma of the head and neck: current knowledge and future directions. Cancer Treat Rev. 2014 Apr; 40(3):390-404.
View in: PubMed

Haddad RI. How to incorporate new tyrosine kinase inhibitors in the treatment of patients with medullary thyroid cancer. J Clin Oncol. 2013 Oct 10; 31(29):3618-20.
View in: PubMed

Pfister DG, Ang KK, Brizel DM, Burtness BA, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Schuller DE, Shah JP, Spencer S, Weber RS, Wolf GT, Worden F, Yom SS, McMillian NR, Hughes M. Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2013 Aug; 11(8):917-23.
View in: PubMed

Haddad R. Larynx preservation: a debate worth preserving. J Clin Oncol. 2013 Sep 01; 31(25):3170.
View in: PubMed

Chapuy CI, Annino DJ, Tishler RB, Haddad RI, Snavely A, Goguen LA. Success of endoscopic pharyngoesophageal dilation after head and neck cancer treatment. Laryngoscope. 2013 Dec; 123(12):3066-73.
View in: PubMed

Gross ND, Pai SI, Haddad RI, Gillison ML, Posner MR. Oral HPV infection in HPV-positive oropharyngeal cancer cases and their spouses. J Clin Oncol. 2013 Jun 20; 31(18_suppl):CRA6031.
View in: PubMed

Liao RG, Jung J, Tchaicha J, Wilkerson MD, Sivachenko A, Beauchamp EM, Liu Q, Pugh TJ, Pedamallu CS, Hayes DN, Gray NS, Getz G, Wong KK, Haddad RI, Meyerson M, Hammerman PS. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res. 2013 Aug 15; 73(16):5195-205.
View in: PubMed

Limaye S, Riley S, Zhao S, O'Neill A, Posner M, Adkins D, Jaffa Z, Clark J, Haddad R. A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN). Oral Oncol. 2013 Aug; 49(8):835-41.
View in: PubMed

Haddad RI. New developments in thyroid cancer. J Natl Compr Canc Netw. 2013 May; 11(5 Suppl):705-7.
View in: PubMed

Misiukiewicz KJ, Camille N, Tishler R, Haddad R, Limaye S, Posner M. Organ preservation for adenoid cystic carcinoma of the larynx. Oncologist. 2013; 18(5):579-83.
View in: PubMed

Hanna J, Reimann JD, Haddad RI, Krane JF. Human papillomavirus-associated adenocarcinoma of the base of the tongue. Hum Pathol. 2013 Aug; 44(8):1516-23.
View in: PubMed

Hanna GJ, Haddad RI, Lorch JH. Induction chemotherapy for locoregionally advanced head and neck cancer: past, present, future? Oncologist. 2013; 18(3):288-93.
View in: PubMed

Limaye SA, Posner MR, Krane JF, Fonfria M, Lorch JH, Dillon DA, Shreenivas AV, Tishler RB, Haddad RI. Trastuzumab for the treatment of salivary duct carcinoma. Oncologist. 2013; 18(3):294-300.
View in: PubMed

Haddad R, O'Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, Clark J, Sarlis N, Lorch J, Beitler JJ, Limaye S, Riley S, Posner M. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol. 2013 Mar; 14(3):257-64.
View in: PubMed

Cmelak AJ, Arneson K, Chau NG, Gilbert RW, Haddad RI. Locally advanced head and neck cancer. Am Soc Clin Oncol Educ Book. 2013; 237-44.
View in: PubMed

Chau NG, Haddad RI. Vandetanib for the treatment of medullary thyroid cancer. Clin Cancer Res. 2013 Feb 01; 19(3):524-9.
View in: PubMed

Shah SM, Drage MG, Lichtman AH, Haddad RI. Metastatic human papillomavirus-positive nasopharyngeal carcinoma with an unusual pattern of aggressive hematogenous spread. J Clin Oncol. 2012 Nov 10; 30(32):e321-3.
View in: PubMed

Liang C, Marsit CJ, McClean MD, Nelson HH, Christensen BC, Haddad RI, Clark JR, Wein RO, Grillone GA, Houseman EA, Halec G, Waterboer T, Pawlita M, Krane JF, Kelsey KT. Biomarkers of HPV in head and neck squamous cell carcinoma. Cancer Res. 2012 Oct 01; 72(19):5004-13.
View in: PubMed

Bou Khalil R, Rohayem J, Abou Said N, El Chammay R, Haddad R, Richa S. Metabolic syndrome (MetS) in Lebanese patients with schizophrenia receiving atypical antipsychotic drugs. Asian J Psychiatr. 2013 Feb; 6(1):88-9.
View in: PubMed

Biselli JM, Zampieri BL, Goloni-Bertollo EM, Haddad R, Fonseca MF, Eberlin MN, Vannucchi H, Carvalho VM, Pavarino EC. Genetic polymorphisms modulate the folate metabolism of Brazilian individuals with Down syndrome. Mol Biol Rep. 2012 Oct; 39(10):9277-84.
View in: PubMed

Rabinowits G, Haddad RI. Overcoming resistance to EGFR inhibitor in head and neck cancer: a review of the literature. Oral Oncol. 2012 Nov; 48(11):1085-9.
View in: PubMed

Haigentz M, Kim M, Sarta C, Lin J, Keresztes RS, Culliney B, Gaba AG, Smith RV, Shapiro GI, Chirieac LR, Mariadason JM, Belbin TJ, Greally JM, Wright JJ, Haddad RI. Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer. Oral Oncol. 2012 Dec; 48(12):1281-8.
View in: PubMed

Sher DJ, Thotakura V, Balboni TA, Norris CM, Haddad RI, Posner MR, Lorch J, Goguen LA, Annino DJ, Tishler RB. Treatment of oropharyngeal squamous cell carcinoma with IMRT: patterns of failure after concurrent chemoradiotherapy and sequential therapy. Ann Oncol. 2012 Sep; 23(9):2391-2398.
View in: PubMed

Lu W, Wayne PM, Davis RB, Buring JE, Li H, Goguen LA, Rosenthal DS, Tishler RB, Posner MR, Haddad RI. Acupuncture for dysphagia after chemoradiation in head and neck cancer: rationale and design of a randomized, sham-controlled trial. Contemp Clin Trials. 2012 Jul; 33(4):700-11.
View in: PubMed

Pfister DG, Ang KK, Brizel DM, Burtness B, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Sanguineti G, Schuller DE, Shah JP, Spencer S, Trotti A, Weber RS, Wolf G, Worden F. Mucosal melanoma of the head and neck. J Natl Compr Canc Netw. 2012 Mar; 10(3):320-38.
View in: PubMed

Cooley ME, Wang Q, Johnson BE, Catalano P, Haddad RI, Bueno R, Emmons KM. Factors associated with smoking abstinence among smokers and recent-quitters with lung and head and neck cancer. Lung Cancer. 2012 May; 76(2):144-9.
View in: PubMed

Chapuy CI, Annino DJ, Snavely A, Li Y, Tishler RB, Norris CM, Haddad RI, Goguen LA. Swallowing function following postchemoradiotherapy neck dissection: review of findings and analysis of contributing factors. Otolaryngol Head Neck Surg. 2011 Sep; 145(3):428-34.
View in: PubMed

Wu Y, Posner MR, Schumaker LM, Nikitakis N, Goloubeva O, Tan M, Lu C, Iqbal S, Lorch J, Sarlis NJ, Haddad RI, Cullen KJ. Novel biomarker panel predicts prognosis in human papillomavirus-negative oropharyngeal cancer: an analysis of the TAX 324 trial. Cancer. 2012 Apr 01; 118(7):1811-7.
View in: PubMed

Anderson KS, Wong J, D'Souza G, Riemer AB, Lorch J, Haddad R, Pai SI, Longtine J, McClean M, LaBaer J, Kelsey KT, Posner M. Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer. Br J Cancer. 2011 Jun 07; 104(12):1896-905.
View in: PubMed

Pfister DG, Ang KK, Brizel DM, Burtness BA, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Sanguineti G, Schuller DE, Shah JP, Spencer S, Trotti A, Weber RS, Wolf GT, Worden F. Head and neck cancers. J Natl Compr Canc Netw. 2011 Jun 01; 9(6):596-650.
View in: PubMed

Cohen L, Chandwani K, Raghuram NV, Haddad R, Perkins GH, Spelman A, Nagarathna R, Johnson K, Fortier A, Arun B, Wei Q, Kirschbaum C, Nagendra HR. Effect of yoga on QOL, cortisol rhythym, and HRV for women with breast cancer undergoing radiotherapy. J Clin Oncol. 2011 May 20; 29(15_suppl):9009.
View in: PubMed

Sher DJ, Thotakura V, Balboni TA, Norris CM, Haddad RI, Posner MR, Lorch J, Goguen LA, Annino DJ, Tishler RB. Treatment of oral cavity squamous cell carcinoma with adjuvant or definitive intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):e215-22.
View in: PubMed

Mawardi H, Elad S, Correa ME, Stevenson K, Woo SB, Almazrooa S, Haddad R, Antin JH, Soiffer R, Treister N. Oral epithelial dysplasia and squamous cell carcinoma following allogeneic hematopoietic stem cell transplantation: clinical presentation and treatment outcomes. Bone Marrow Transplant. 2011 Jun; 46(6):884-91.
View in: PubMed

Posner MR, Lorch JH, Goloubeva O, Tan M, Schumaker LM, Sarlis NJ, Haddad RI, Cullen KJ. Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol. 2011 May; 22(5):1071-1077.
View in: PubMed

Sher DJ, Posner MR, Tishler RB, Sarlis NJ, Haddad RI, Holupka EJ, Devlin PM. Relationship between radiation treatment time and overall survival after induction chemotherapy for locally advanced head-and-neck carcinoma: a subset analysis of TAX 324. Int J Radiat Oncol Biol Phys. 2011 Dec 01; 81(5):e813-8.
View in: PubMed

Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, Tan M, Fasciano J, Sammartino DE, Posner MR. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol. 2011 Feb; 12(2):153-9.
View in: PubMed

Cooley ME, Emmons KM, Haddad R, Wang Q, Posner M, Bueno R, Cohen TJ, Johnson BE. Patient-reported receipt of and interest in smoking-cessation interventions after a diagnosis of cancer. Cancer. 2011 Jul 01; 117(13):2961-9.
View in: PubMed

Cooley ME, Emmons KM, Haddad R, Wang Q, Posner M, Bueno R, Cohen TJ, Johnson BE. Patient-reported receipt of and interest in smoking-cessation interventions after a diagnosis of cancer. Cancer. 2011 Jan 10.
View in: PubMed

Sher DJ, Balboni TA, Haddad RI, Norris CM, Posner MR, Wirth LJ, Goguen LA, Annino D, Tishler RB. Efficacy and toxicity of chemoradiotherapy using intensity-modulated radiotherapy for unknown primary of head and neck. Int J Radiat Oncol Biol Phys. 2011 Aug 01; 80(5):1405-11.
View in: PubMed

Schoenfeld JD, Sher DJ, Norris CM, Haddad RI, Posner MR, Balboni TA, Tishler RB. Salivary gland tumors treated with adjuvant intensity-modulated radiotherapy with or without concurrent chemotherapy. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):308-14.
View in: PubMed

Tuttle RM, Ball DW, Byrd D, Dilawari RA, Doherty GM, Duh QY, Ehya H, Farrar WB, Haddad RI, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey JC, Olson JA, Parks L, Ridge JA, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ. Thyroid carcinoma. J Natl Compr Canc Netw. 2010 Nov; 8(11):1228-74.
View in: PubMed

Sher DJ, Haddad RI, Norris CM, Posner MR, Wirth LJ, Goguen LA, Annino D, Balboni T, Allen A, Tishler RB. Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer. Cancer. 2010 Oct 15; 116(20):4761-8.
View in: PubMed

Goguen LA, Chapuy CI, Sher DJ, Israel DA, Blinder RA, Norris CM, Tishler RB, Haddad RI, Annino DJ. Utilizing computed tomography as a road map for designing selective and superselective neck dissection after chemoradiotherapy. Otolaryngol Head Neck Surg. 2010 Sep; 143(3):367-74.
View in: PubMed

Lu W, Posner MR, Wayne P, Rosenthal DS, Haddad RI. Acupuncture for dysphagia after chemoradiation therapy in head and neck cancer: a case series report. Integr Cancer Ther. 2010 Sep; 9(3):284-90.
View in: PubMed

Agoston ES, Robinson SJ, Mehra KK, Birch C, Semmel D, Mirkovic J, Haddad RI, Posner MR, Kindelberger D, Krane JF, Brodsky J, Crum CP. Polymerase chain reaction detection of HPV in squamous carcinoma of the oropharynx. Am J Clin Pathol. 2010 Jul; 134(1):36-41.
View in: PubMed

Tuttle RM, Ball DW, Byrd D, Daniels GH, Dilawari RA, Doherty GM, Duh QY, Ehya H, Farrar WB, Haddad RI, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey J, Olson JA, Parks L, Ridge JA, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ. Medullary carcinoma. J Natl Compr Canc Netw. 2010 May; 8(5):512-30.
View in: PubMed

Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab. 2010 Jun; 95(6):2664-71.
View in: PubMed

Goguen LA, Norris CM, Jaklitsch MT, Sullivan CA, Posner MR, Haddad RI, Tishler RB, Burke E, Annino DJ. Combined antegrade and retrograde esophageal dilation for head and neck cancer-related complete esophageal stenosis. Laryngoscope. 2010 Feb; 120(2):261-6.
View in: PubMed

Cullen KJ, Schumaker L, Nikitakis N, Goloubeva O, Tan M, Sarlis NJ, Haddad RI, Posner MR. beta-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial. J Clin Oncol. 2009 Dec 20; 27(36):6222-8.
View in: PubMed

Wirth LJ, Allen AM, Posner MR, Haddad RI, Li Y, Clark JR, Busse PM, Chan AW, Goguen LA, Norris CM, Annino DJ, Tishler RB. Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. Ann Oncol. 2010 Feb; 21(2):342-347.
View in: PubMed

Haddad R, Sonis S, Posner M, Wirth L, Costello R, Braschayko P, Allen A, Mahadevan A, Flynn J, Burke E, Li Y, Tishler RB. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer. 2009 Oct 01; 115(19):4514-23.
View in: PubMed

Haddad RI, Tishler RB, Norris C, Goguen L, Balboni TA, Costello R, Wirth L, Lorch J, Andreozzi B, Annino D, Posner MR. Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 2009 Sep 20; 27(27):4448-53.
View in: PubMed

Settle K, Posner MR, Schumaker LM, Tan M, Suntharalingam M, Goloubeva O, Strome SE, Haddad RI, Patel SS, Cambell EV, Sarlis N, Lorch J, Cullen KJ. Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res (Phila). 2009 Sep; 2(9):776-81.
View in: PubMed

Haddad RI, Posner MR. Induction chemotherapy in head and neck cancer. J Clin Oncol. 2009 Aug 10; 27(23):e52-3; author reply e54.
View in: PubMed

Haddad RI. Re: Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst. 2009 Aug 19; 101(16):1157-8; author reply 1158.
View in: PubMed

Wirth LJ, Fogg M, Wang F, Lorch J, Haddad RI, Posner MR. Epstein-Barr virus (EBV)-specific immunotherapy in nasopharygneal carcinoma (NPC). J Clin Oncol. 2009 May 20; 27(15_suppl):6025.
View in: PubMed

Salama JK, Haddad RI, Kies MS, Busse PM, Dong L, Brizel DM, Eisbruch A, Tishler RB, Trotti AM, Garden AS. Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2009 Nov 01; 75(3):725-33.
View in: PubMed

Posner MR, Norris CM, Wirth LJ, Shin DM, Cullen KJ, Winquist EW, Blajman CR, Mickiewicz EA, Frenette GP, Plinar LF, Cohen RB, Steinbrenner LM, Freue JM, Gorbunova VA, Tjulandin SA, Raez LE, Adkins DR, Tishler RB, Roessner MR, Haddad RI. Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. Ann Oncol. 2009 May; 20(5):921-7.
View in: PubMed

Salama J*, Haddad R*, Kies M, Busse P, Dong L, Brizel D, Eisbruch A, Tishler R, Trotti A, Garden A. Clinical Practice Guidance For Radiotherapy Planning Following Induction Chemotherapy In Locoregionally Advanced Head And Neck Cancer . International Journal of Radiation Oncology, Biology, Physics . 2009; In Press.
View in: PubMed

Lorch J, Posner MR, Wirth LJ, Haddad RI. . Seeking alternative biological therapies. The future of targeted molecular treatment. Oral Oncology-In Press. 2008.
View in: PubMed

Lorch JH, Posner MR, Wirth LJ, Haddad RI. Induction chemotherapy in locally advanced head and neck cancer: a new standard of care? Hematol Oncol Clin North Am. 2008 Dec; 22(6):1155-63, viii.
View in: PubMed

Corey Langer, Robert Haddad, David Rosenthal, Everett Vokes. Head and Neck Cancer Update: Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care.(Online CME). 2008.
View in: PubMed

Lorch JH, Posner MR, Wirth LJ, Haddad RI. Seeking alternative biological therapies: the future of targeted molecular treatment. Oral Oncol. 2009 Apr-May; 45(4-5):447-53.
View in: PubMed

Robert Haddad. Recurrent Squamous Cell Carcinoma of the Tongue. 2008.
View in: PubMed

Marshall R. Posner, Charles M. Norris, Lori J. Wirth, Dong M. Shin, Kevin J. Cullen, Eric W. Winquist, Cesar R. Blajman, Elizabeth A. Mickiewicz, Gary P. Frenette, Lillian F. Plinar, Roger B. Cohen, Lynn M. Steinbrenner, Jose M. Freue, Vera A. Gorbunova, Sergei A. Tjulandin, Luis E. Raez, Douglas R. Adkins, Roy B. Tishler, Martin R. Roessner, and Robert I. Haddad. Sequential Therapy for the Locally Advanced Larynx and Hypopharynx Cancer Subgroup in TAX 324: Survival, Surgery, and Organ Preservation. Annals of Oncology-In Press. 2008.
View in: PubMed

Wirth LJ, Krane JF, Li Y, Othus M, Moran AE, Dorfman DM, Norris CM, Goguen L, Posner MR, Haddad RI, Bertagnolli MM. A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions. Cancer Prev Res (Phila). 2008 Oct; 1(5):339-48.
View in: PubMed

Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med. 2008 Sep 11; 359(11):1143-54.
View in: PubMed

Russo G, Haddad R, Posner M, Machtay M. Radiation treatment breaks and ulcerative mucositis in head and neck cancer. Oncologist. 2008 Aug; 13(8):886-98.
View in: PubMed

Haddad R. Trends in Head and Neck Cancer. The American Journal of Hematology/Oncology. 2008; 7(8):323-324.
View in: PubMed

Caglar HB, Tishler RB, Othus M, Burke E, Li Y, Goguen L, Wirth LJ, Haddad RI, Norris CM, Court LE, Aninno DJ, Posner MR, Allen AM. Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2008 Nov 15; 72(4):1110-8.
View in: PubMed

Wirth LJ, Posner MR, Tishler RB, Haddad RI, Clark JR, Goguen L, Norris CM, Annino D, Costello R, Allen AM. Phase I study of panitumumab + chemoradiotherapy (CRT) for head and neck cancer (HNC). J Clin Oncol. 2008 May 20; 26(15_suppl):6007.
View in: PubMed

Haddad RI, Krebs AD, Vasselli J, Paz-Ares LG, Robinson B. A phase II open-label study of vandetanib in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):6024.
View in: PubMed

Posner MR, Norris CM, Tishler RB, Wirth LJ, Haddad RI. Sequential therapy for locally advanced larynx and hypopharynx cancer: Subgroup analysis from the TAX 324 Study. J Clin Oncol. 2008 May 20; 26(15_suppl):6031.
View in: PubMed

Tishler RB, Posner MR, Wirth LJ, Balboni T, Costello R, Goguen L, Annino D, Livada N, Norris CM, Haddad RI. Cetuximab added to docetaxel, cisplatin, 5-fluorouracil Induction chemotherapy (C-TPF) in patients with newly diagnosed locally advanced head and neck cancer: A phase I study. J Clin Oncol. 2008 May 20; 26(15_suppl):6001.
View in: PubMed

M. R. Posner, C. M. Norris, R. B. Tishler, L. J. Wirth, R. I. Haddad, TAX 324 Study Group. Sequential therapy for locally advanced larynx and hypopharynx cancer: Subgroup analysis from the TAX 324 Study. J Clin Oncol 26: 2008 (May 20 suppl; abstr 6031). 2008.
View in: PubMed

R. I. Haddad, A. D. Krebs, J. Vasselli, L. G. Paz-Ares, B. Robinson. A phase II open-label study of vandetanib in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 26: 2008 (May 20 suppl; abstr 6024). 2008.
View in: PubMed

R. B. Tishler, M. R. Posner, L. J. Wirth, T. Balboni, R. Costello, L. Goguen, D. Annino, N. Livada, C. M. Norris, R. I. Haddad. Cetuximab added to docetaxel, cisplatin, 5-fluorouracil Induction chemotherapy (C-TPF) in patients with newly diagnosed locally advanced head and neck cancer: A phase I study. J Clin Oncol 26: 2008 (May 20 suppl; abstr 6001). 2008.
View in: PubMed

L. J. Wirth, M. R. Posner, R. B. Tishler, R. I. Haddad, J. R. Clark, L. Goguen, C. M. Norris, D. Annino, R. Costello, A. M. Allen. Phase I study of panitumumab + chemoradiotherapy (CRT) for head and neck cancer (HNC). J Clin Oncol 26: 2008 (May 20 suppl; abstr 6007). 2008.
View in: PubMed

Haddad R. Human Papillomavirus Infection and Oropharynx Cancer. Published in "News from S.P.O.H.N.C" Support for People with Oral and Head and Neck Cancer. 2008.
View in: PubMed

Pennell NA, Daniels GH, Haddad RI, Ross DS, Evans T, Wirth LJ, Fidias PH, Temel JS, Gurubhagavatula S, Heist RS, Clark JR, Lynch TJ. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid. 2008 Mar; 18(3):317-23.
View in: PubMed

Haddad R, Annino D, Tishler RB. Multidisciplinary approach to cancer treatment: focus on head and neck cancer. Dent Clin North Am. 2008 Jan; 52(1):1-17, vii.
View in: PubMed

Biselli JM, Goloni-Bertollo EM, Haddad R, Eberlin MN, Pavarino-Bertelli EC. The MTR A2756G polymorphism is associated with an increase of plasma homocysteine concentration in Brazilian individuals with Down syndrome. Braz J Med Biol Res. 2008 Jan; 41(1):34-40.
View in: PubMed

Haddad R, Crum C, Chen Z, Krane J, Posner M, Li Y, Burk R. HPV16 transmission between a couple with HPV-related head and neck cancer. Oral Oncol. 2008 Aug; 44(8):812-5.
View in: PubMed

Biselli PM, Sanches de Alvarenga MP, Abbud-Filho M, Ferreira-Baptista MA, Galbiatti AL, Goto MT, Cardoso MA, Eberlin MN, Haddad R, Goloni-Bertollo EM, Pavarino-Bertelli EC. Effect of folate, vitamin B6, and vitamin B12 intake and MTHFR C677T polymorphism on homocysteine concentrations of renal transplant recipients. Transplant Proc. 2007 Dec; 39(10):3163-5.
View in: PubMed

Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM, Haddad RI. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007 Oct 25; 357(17):1705-15.
View in: PubMed

Posner MR, Haddad RI. Novel agents for the treatment of mucositis. J Support Oncol. 2007 Oct; 5(9 Suppl 4):33-9.
View in: PubMed

Chambers MS, Jones CU, Biel MA, Weber RS, Hodge KM, Chen Y, Holland JM, Ship JA, Vitti R, Armstrong I, Garden AS, Haddad R. Open-label, long-term safety study of cevimeline in the treatment of postirradiation xerostomia. Int J Radiat Oncol Biol Phys. 2007 Dec 01; 69(5):1369-76.
View in: PubMed

Robert Haddad. Human Papillomavirus Infection and Oropharyngeal Cancer.(Online CME). 2007.
View in: PubMed

Haddad R. Trends in Head and Neck Cancer. The American Journal of Hematology/Oncology. 2007; Vol 6. No 4(4):187-188.
View in: PubMed

Muñoz AA, Haddad RI, Woo SB, Bhattacharyya N. Behavior of oral squamous cell carcinoma in subjects with prior lichen planus. Otolaryngol Head Neck Surg. 2007 Mar; 136(3):401-4.
View in: PubMed

Allen AM, Haddad RI, Tishler RB. Retropharyngeal nodes in hypopharynx cancer on positron emission tomography. J Clin Oncol. 2007 Feb 10; 25(5):599-601.
View in: PubMed

Mager DL, Haddad RI, Wirth LJ, Haffajee AD. . Oral Mucous Membrane Macrobiotica in Health and Oral Squamous Cell Carcinoma. Grand Rounds in Oral-Systemic Medicine. 2007; 2(1):12-8.
View in: PubMed

Haigentz, Jr., M, Adrein LR, Belbin TJ, Greally JM, Mariadson JM, Shapiro GI, Chirieac LR, Signoretti S, Brandwein-Gensler M, Kim M, Wright JJ, Sarta C, Smith RV, Haddad RI. . Translational studies of depsipeptide, a histone deacetylase (HDAC) inhibitor in patients with head and neck cancer [abstract]. Proc Am Assoc Cancer Res 48: A3524 . 2007.
View in: PubMed

Wirth LJ, Posner MR, Tishler RB, Haddad RI, Goguen LA, Clark JR, Allen AM. . Phase I study of panitumumab, chemotherapy, and intensity-modulated radiotherapy (IMRT) for head and neck cancer (HNC): Early results. . Proc Am Soc Clin Oncol 1/1/2007; 25: Abstr #6083. 2007.
View in: PubMed

Allen A, Posner M, Haddad R, Wirth L, Burke E, Goguen L, Norris C, Annino D, Tishler R. . Swallowing function after IMRT and chemotherapy for head and neck cancer. Proc Am Soc Clin Oncol 1/1/2007; 25: Abstr #6046 . Proc Am Soc Clin Oncol 1/1/2007; 25: Abstr #6046. 2007.
View in: PubMed

Haddad R, Posner M. Head and Neck Carcinoma: American College of Physicians (ACP) On-line publication, Physicians Information and Education Resource (PIER). . Online. 2007.
View in: PubMed

de Alvarenga MP, Pavarino-Bertelli EC, Abbud-Filho M, Ferreira-Baptista MA, Haddad R, Eberlin MN, Goloni-Bertollo EM. Combination of angiotensin-converting enzyme and methylenetetrahydrofolate reductase gene polymorphisms as determinant risk factors for chronic allograft dysfunction. Transplant Proc. 2007 Jan-Feb; 39(1):78-80.
View in: PubMed

Haigentz, Jr M, Kim M, Sarta C, Keresztes RS, Smith RV, Belbin TJ, Mariadson JM, Greally JM, Shapiro GI, Haddad RI. . Clinical and translational studies of depsipeptide, a histone deacetylase inhibitor, in patients with squamous cell carcinoma of the head and neck: New York Cancer Consortium Trial P6335 [abstract]. Proc Am Soc Clin Oncol 1/1/2007; 25: A6065 . 2007.
View in: PubMed

Robert Haddad, Marshall Posner. Changing Paradigms in the Treatment of Squamous Cell Carcinoma of the Head and Neck. (Online CME). 2006.
View in: PubMed

Pulvermacker B, Seroussi D, Haddad R, Mitrofanoff M. [Pilomatricoma or calcifying epithelioma of Malherbe. A pediatric review of 89 cases]. Ann Chir Plast Esthet. 2007 Feb; 52(1):39-42.
View in: PubMed

Haddad R, Wirth L, Posner M. Emerging drugs for head and neck cancer. Expert Opin Emerg Drugs. 2006 Sep; 11(3):461-7.
View in: PubMed

Sonis S, Haddad R, Posner M, Watkins B, Fey E, Morgan TV, Mookanamparambil L, Ramoni M. Gene expression changes in peripheral blood cells provide insight into the biological mechanisms associated with regimen-related toxicities in patients being treated for head and neck cancers. Oral Oncol. 2007 Mar; 43(3):289-300.
View in: PubMed

Epelbaum R, Bar-Shalom R, Keidar Z, Gaitini D, Haddad R, Israel O. PET/CT imaging in patients with suspected recurrence of pancreatic cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):14137.
View in: PubMed

Haddad R, Tishler R, Wirth L, Norris CM, Goguen L, Sullivan C, O'Donnell L, Li Y, Posner M. Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2006 Jun; 132(6):678-81.
View in: PubMed

Goguen LA, Posner MR, Norris CM, Tishler RB, Wirth LJ, Annino DJ, Gagne A, Sullivan CA, Sammartino DE, Haddad RI. Dysphagia after sequential chemoradiation therapy for advanced head and neck cancer. Otolaryngol Head Neck Surg. 2006 Jun; 134(6):916-22.
View in: PubMed

Tishler RB, Posner MR, Norris CM, Mahadevan A, Sullivan C, Goguen L, Wirth LJ, Costello R, Case M, Stowell S, Sammartino D, Busse PM, Haddad RI. Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys. 2006 Jul 15; 65(4):1036-44.
View in: PubMed

Goguen LA, Posner MR, Tishler RB, Wirth LJ, Norris CM, Annino DJ, Sullivan CA, Li Y, Haddad RI. Examining the need for neck dissection in the era of chemoradiation therapy for advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 2006 May; 132(5):526-31.
View in: PubMed

Haddad RI, Posner MR, Busse PM, Norris CM, Goguen LA, Wirth LJ, Blinder R, Krane JF, Tishler RB. Chemoradiotherapy for adenoid cystic carcinoma: preliminary results of an organ sparing approach. Am J Clin Oncol. 2006 Apr; 29(2):153-7.
View in: PubMed

Haddad R. Current and future directions in the treatment of squamous cell carcinoma of the head and neck: multidisciplinary symposium on head and neck cancer. Expert Opin Ther Targets. 2006 Apr; 10(2):333-6.
View in: PubMed

Haddad R, Allen A, Wirth L, Tishler R, Posner M. Integrating novel agents in the curative treatment of head and neck cancer. Exp. Rev, Anti. Ther. 2006; 6(2):157-9.
View in: PubMed

Haddad R, Allen A, Wirth L, Tishler R, Posner M. Integrating novel agents into the curative treatment of head and neck cancer. Expert Rev Anticancer Ther. 2006 Feb; 6(2):157-9.
View in: PubMed

Haddad R. Cetuximab in squamous cell carcinoma of the head and neck. Am. J. Onc. Rev. 2006; 1(1).
View in: PubMed

R. I. Haddad, M. Ramoni, M. Posner, B. Watkins, E. Fey, L. Mookanamparambil, T. Morgan, S. Sonis. Use of Peripheral Blood Monocytes (PBM) to Define Changes in Gene Expression Associated with Amifostine Treatment And Their Association With Oral Mucositis (OM) In Patients Being Treated With Chemoradiotherapy For Squamous Cell Carcinoma of the Head and Neck (SCCHN). American Society of Therapeutic Radiation Oncology (ASTRO) Meeting. 2006.
View in: PubMed

Posner M, Hershock D, Le-Lan L, Devlin P, Haddad R. A phase III trial of TPF vs. PF Induction Chemotherapy Followed by chemoradiotherapy in Locally Advanced SCCHN. Special Session ASCO. 2006.
View in: PubMed

Posner M, Haddad R, Wirth L. The Evolution of induction chemotherapy and sequential therapy for locally advanced squamous cell cancer of the head and neck. ASCO Educational Book. 2006; 346-52.
View in: PubMed

M. S. Chambers, K. Hodge, J. Holland, C. Jones, R. Vitti, A.S. Garden, R.I. Haddad. A Phase III Open-Label, Long-Term Safety Study of Cevimeline Hydrochloride in Patients with Xerostomia Secondary to Radiation Therapy for Cancer in the Head and Neck Region. ASTRO Meeting. 2006.
View in: PubMed

Wirth LJ, Haddad RI, Lindeman NI, Zhao X, Lee JC, Joshi VA, Norris CM, Posner MR. Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2005 Oct 01; 23(28):6976-81.
View in: PubMed

Guadagnolo BA, Haddad RI, Posner MR, Weeks L, Wirth LJ, Norris CM, Sullivan CA, Goguen L, Busse PM, Tishler R. Organ preservation and treatment toxicity with induction chemotherapy followed by radiation therapy or chemoradiation for advanced laryngeal cancer. Am J Clin Oncol. 2005 Aug; 28(4):371-8.
View in: PubMed

Wirth LJ, Moran AE, Krane JF, Weeks L, Norris CM, Goguen LA, Sullivan CA, Haddad RI, Posner MR, Bertagnolli MM. Pilot study of celecoxib in oral premalignant lesions (OPLs): Preliminary results. J Clin Oncol. 2005 Jun; 23(16_suppl):1025.
View in: PubMed

Haddad RI, Tishler R, Wirth L, Norris C, Goguen L, Sullivan C, O'Donnell L, Li Y, Posner MR. Rate of complete pathological responses (pCR) to docetaxel/cisplatin/5-fluorouracil (TPF) induction chemotherapy in patients with newly diagnosed, locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol. 2005 Jun; 23(16_suppl):5511.
View in: PubMed

Sullivan CA, Haddad RI, Tishler RB, Mahadevan A, Krane JF. Chemoradiation-induced cell loss in human submandibular glands. Laryngoscope. 2005 Jun; 115(6):958-64.
View in: PubMed

Haddad R, Mahadevan A, Posner MR, Sullivan C. Long term survival with adjuvant carboplatin, paclitaxel, and radiation therapy in anaplastic thyroid cancer. Am J Clin Oncol. 2005 Feb; 28(1):104.
View in: PubMed

Haddad R, Posner M, Wirth L, et. al. Concomitant Chemoradiation Using Weekly Carboplatin/Paclitaxel With or Without Daily Subcutaneous Amifostine in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck. ASTRO meeting 2005. Denver , CO. IJROBP supplement. 2005; 63, 2:2229.
View in: PubMed

Gokhale AS, Haddad RI, Cavacini LA, Wirth L, Weeks L, Hallar M, Faucher J, Posner MR. Serum concentrations of interleukin-8, vascular endothelial growth factor, and epidermal growth factor receptor in patients with squamous cell cancer of the head and neck. Oral Oncol. 2005 Jan; 41(1):70-6.
View in: PubMed

Posner MR, Wirth L, Tishler RB, Norris CM, Haddad. RI. The Evolution of Induction Chemotherapy in Locally Advanced Squamous Cell Cancer of the Head and Neck: The New Paradigm of Sequential Therapy. Head and Neck Cancer, Adelstein, D (ed). 2005; 171-86.
View in: PubMed

Posner MR, Haddad RI, Wirth L, Norris CM, Goguen LA, Mahadevan A, Sullivan C, Tishler RB. Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach. Semin Oncol. 2004 Dec; 31(6):778-85.
View in: PubMed

Sullivan CA, Jaklitsch MT, Haddad R, Goguen LA, Gagne A, Wirth LJ, Posner MR, Tishler RB, Norris CM. Endoscopic management of hypopharyngeal stenosis after organ sparing therapy for head and neck cancer. Laryngoscope. 2004 Nov; 114(11):1924-31.
View in: PubMed

McCollum AD, Burrell SC, Haddad RI, Norris CM, Tishler RB, Case MA, Posner MR, Van den Abbeele AD. Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer. Head Neck. 2004 Oct; 26(10):890-6.
View in: PubMed

Tishler RB, Haddad RI, Norris CM, Sullivan C, Mahadevan A, Wirth L, Goguen L, Nixon A, Stowell S, Posner MR. A phase I/II study of docetaxel (D) and concomitant boost radiation (CBR) for patients with squamous cell cancer of the head and neck (SCCHN) following induction chemotherapy (IC). J Clin Oncol. 2004 Jul 15; 22(14_suppl):5548.
View in: PubMed

Wirth LJ, Haddad RI, Wieczorek TJ, Faucher JL, Clark JR, Norris CM, Posner MR. Phase I study of gefitinib plus celecoxib in patients with metastatic and/or locally recurrent squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol. 2004 Jul 15; 22(14_suppl):5540.
View in: PubMed

Haddad RI, Gokhale AS, Wirth L, Weeks L, Faucher J, Hallar M, Cavacini LA, Posner MR. Interleukin-8 (IL-8) serum levels and squamous cell cancer of the head and neck (SCCHN). J Clin Oncol. 2004 Jul 15; 22(14_suppl):9716.
View in: PubMed

Guadagnolo BA, Tishler RB, Posner MR, Weeks L, Wirth LJ, Norris CM, Sullivan CA, Goguen L, Busse PM, Haddad RI. Organ preservation for patients treated with induction chemotherapy (IC) followed by radiation therapy (RT) or chemoradiation (CRT) for advanced stage squamous cell carcinoma of the larynx (SCCL). J Clin Oncol. 2004 Jul 15; 22(14_suppl):5600.
View in: PubMed

Haddad R, Gokhe A, Wirth L, et. al. Interleukin-8 (IL-8) Serum Levels and Squamous Cell Cancer of the Head and Neck (SCCHN). Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition)(July 15 Supplement). 2004; 22 No14S:9716.
View in: PubMed

R. B. Tishler, C.M. Norris, R. I. Haddad, et. al. A phase I/II study of docetaxel (D) and concomitant boost radiation (CBR) for patients with squamous cell cancer of the head and neck (SCCHN) following induction chemotherapy (IC). Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition)(July 15 Supplement). 2004; 22, No 14S:5548.
View in: PubMed

LJ Wirth, RI Haddad, TJ Wieczorek, et. al. Phase I study of gefitinib plus celecoxib in patients with metastatic and/or locally recurrent squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition) (July 15 Supplement). 2004; 22, No 14S:5540.
View in: PubMed

Haddad RI, Weinstein LJ, Wieczorek TJ, Bhattacharya N, Raftopoulos H, Oster MW, Zhang X, Latham VM, Costello R, Faucher J, DeRosa C, Yule M, Miller LP, Loda M, Posner MR, Shapiro GI. A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor. Clin Cancer Res. 2004 Jul 15; 10(14):4680-7.
View in: PubMed

B. A. Guadagnolo, R. B. Tishler, M. R. Posner, L. Weeks, L. J. Wirth, C. M. Norris, C. A. Sullivan, L. Goguen, P. M. Busse, R. I. Haddad. Organ preservation for patients treated with induction chemotherapy (IC) followed by radiation therapy (RT) or chemoradiation (CRT) for advanced stage squamous cell carcinoma of the larynx (SCCL). Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition)(July 15 Supplement). 2004; 22, No 14S:5600.
View in: PubMed

Haddad R. The Role of Epidermal Growth Factor Receptor Inhibitors In Head And Neck Cancer. Am. J. Onc. Rev. 2004; 3(7).
View in: PubMed

Haddad R, Tishler R, Posner M. RE: Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer. N. Engl. J. Med. 2004; 350(10):1051-2.
View in: PubMed

Haddad RI, Tishler RB, Posner MR. Nonsurgical treatment of laryngeal cancer. N Engl J Med. 2004 Mar 04; 350(10):1049-53; author reply 1049-53.
View in: PubMed

Saito EH, Castro MP, Menezes SL, Haddad R, Antonangelo L, Teixeira LR, Negri EM, Capelozzi VL, Rocco PR, Zin WA. Respiratory mechanics and pleural remodelling in pleurodesis induced by barium sulphate. Respir Physiol Neurobiol. 2004 Feb 25; 139(3):271-80.
View in: PubMed

Glisson B, Colevas AD, Haddad R, Krane J, El-Naggar A, Kies M, Costello R, Summey C, Arquette M, Langer C, Amrein PC, Posner M. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res. 2004 Feb 01; 10(3):944-6.
View in: PubMed

Haddad R, Posner M. RE: Erythropoietin to treat head and neck cancer patients with anemia undergoing radiotherapy: randomized, double blind, placebo-controlled trial. Lancet. 2004; 363(9402):79-80.
View in: PubMed

Haddad R, Posner M. Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet. 2004 Jan 03; 363(9402):79-80; author reply 81-2.
View in: PubMed

Smith RC, Korban E, Kanj M, Haddad R, Lyles JS, Lein C, Gardiner JC, Hodges A, Dwamena FC, Coffey J, Collins C. A method for rating charts to identify and classify patients with medically unexplained symptoms. Psychother Psychosom. 2004 Jan-Feb; 73(1):36-42.
View in: PubMed

Haddad R, Wirth L, Costello R, Weeks L, Posner M. Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. Semin Oncol. 2003 Dec; 30(6 Suppl 18):84-8.
View in: PubMed

Haddad R, Colevas AD, Krane JF, Cooper D, Glisson B, Amrein PC, Weeks L, Costello R, Posner M. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol. 2003 Oct; 39(7):724-7.
View in: PubMed

Patel B, Haddad R, Saxena I, Gossain VV. Spontaneous long-term remission in a patient with premature ovarian failure. Endocr Pract. 2003 Sep-Oct; 9(5):380-3.
View in: PubMed

Haddad RI, Van Echo DA. Phase II study of docetaxel and topotecan combination chemotherapy in patients with advanced head and neck cancer. Cancer Chemother Pharmacol. 2003 Oct; 52(4):303-6.
View in: PubMed

Haddad RI, Wirth L, Posner MR. Integration of chemotherapy in the curative treatment of locally advanced head and neck cancer. Expert Rev Anticancer Ther. 2003 Jun; 3(3):331-8.
View in: PubMed

Wirth LJ, Haddad RI, Posner MR. Progress and perspectives in chemoprevention of head and neck cancer. Expert Rev Anticancer Ther. 2003 Jun; 3(3):339-55.
View in: PubMed

Haddad R, Posner M. Palliative Chemotherapy in Patients With Salivary Gland Neoplasms: Review of The Literature and Preliminary Reports of Two Recently Performed Phase II Studies With Single Agents Herceptin And Gemcitabine. Clinical Advances in Hematology & Oncology. 2003; (1):226-8.
View in: PubMed

Haddad R, Posner MR. Palliative chemotherapy in patients with salivary gland neoplasms and preliminary reports of 2 recent phase II studies with trastuzumab and gemcitabine. Clin Adv Hematol Oncol. 2003 Apr; 1(4):226-8.
View in: PubMed

Haddad R, Posner M. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer. 2003 Mar 15; 97(6):1589; author reply 1590.
View in: PubMed

Haddad R, Colevas AD, Tishler R, Busse P, Goguen L, Sullivan C, Norris CM, Lake-Willcutt B, Case MA, Costello R, Posner M. Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience. Cancer. 2003 Jan 15; 97(2):412-8.
View in: PubMed

Haddad R, Shapiro G, Weinstein L, Wieczorek T, Bhattacharya N, Loda M, Raftopolus H, Oster M, Faucher J, Posner M. A Phase II Study of E7070 in Patients with Metastatic, Recurrent, or Refractory Head and Neck Squamous Cell Carcinoma (HNSCC): Clinical activity and post-treatment modulation of Rb phosphorylation. Proc. Am. Soc. Clin. Oncol. (abstr 800) (Poster discussion session). 2003; 22:200.
View in: PubMed

Haddad R, Tishler RB, Norris CM, Mahadevan A, Busse P, Wirth L, Goguen LA, Sullivan CA, Costello R, Case MA, Posner MR. Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment. Oncologist. 2003; 8(1):35-44.
View in: PubMed

Haddad R, Norris C, Posner M. . 49 year old male with locally advanced squamous cell carcinoma of the head and neck: the case for sequential chemoradiotherapy programs. Clin Adv in Hematol Oncol. 2003; 1(1):58-61.
View in: PubMed

Haddad R, Norris CM, Posner MR. A 49-year-old male with locally advanced squamous cell carcinoma of the head and neck: the case for sequential chemoradiotherapy. Clin Adv Hematol Oncol. 2003 Jan; 1(1):58-60; discussion 61-2.
View in: PubMed

Haddad R, Norris C, Sullivan C, Goguen L, Tishler R, Busse P, Lake-Willcutt B, Costello R, Case MA, Posner MR. Docetaxel, Cisplatin and 5-fluouracil (TPF) based induction chemotherapy for locally advanced head and neck cancer: long term survival and salvage. (ASCO Proc). 2002; 21:960.
View in: PubMed

Tishler R, Norris C, Haddad R, Goguen L, Sullivan C, Busse P, Lamb C, Costello R, Case MA, Lake-Willcutt B, Posner M. A Phase I/II Trial Of Concurrent Docetaxel And Concomitant Boost Radiation Therapy For Patients With Squamous Cell Cancer Of The Head And Neck Following Induction Chemotherapy: A Sequential Combined Modality Approach. (ASCO Proc). 2002; 21:2561.
View in: PubMed

Schneebaum S, Troitsa A, Haddad R, Avital S, Kashtan H, Baratz M, Brazovsky E, Papo J, Skornick Y. Immunoguided lymph node dissection in colorectal cancer: a new challenge? World J Surg. 2001 Dec; 25(12):1495-8; discussion 1499.
View in: PubMed

Sarkodee-Adoo C, Pittarelli L, Jaffe E, Sorbara L, Raffeld M, Yao X, Haddad R, Heller T. Regression and clonally distinct recurrence of human immunodeficiency virus related Burkitt-like lymphoma during antiretroviral therapy. Leuk Lymphoma. 2001 Sep-Oct; 42(5):1125-31.
View in: PubMed

Lu Y, Yang Y, Sellinger A, Lu M, Huang J, Fan H, Haddad R, Lopez G, Burns AR, Sasaki DY, Shelnutt J, Brinker CJ. Self-assembly of mesoscopically ordered chromatic polydiacetylene/silica nanocomposites. Nature. 2001 Apr 19; 410(6831):913-7.
View in: PubMed

Karin E, Haddad R, Kashtan H. Segmental resection for recurrent carcinoma of the esophagus. Isr Med Assoc J. 2001 Mar; 3(3):228-9.
View in: PubMed

Suntharalingam M, Haas ML, Van Echo DA, Haddad R, Jacobs MC, Levy S, Gray WC, Ord RA, Conley BA. Predictors of response and survival after concurrent chemotherapy and radiation for locally advanced squamous cell carcinomas of the head and neck. Cancer. 2001 Feb 01; 91(3):548-54.
View in: PubMed

Greenberg R, Haddad R, Kashtan H, Skornick Y, Kaplan O. Effects of intravenous gamma immunoglobulins treatment on severe peritonitis in rats. Int J Surg Investig. 2001; 2(6):433-42.
View in: PubMed

Haddad R, VanEcho DA. Antineoplastic Drug Development. The Chemotherapy Source Book, Perry MC (ed). 2001.
View in: PubMed

Haddad R, Suntharalingam M, Levy S, O’Malley B, Caldwell D, Murthy R, VanEcho DA. Superselective Intraarterial Cisplatin In Patients With Squamous Cell Carcinoma Of The Head And Neck: University Of Maryland Experience. (ASCO Proc). 2001; 20:2562.
View in: PubMed

Haddad R, VanEcho DA, Levy S. A Phase II Trial of Taxotere, Topotecan Combination Chemotherapy in Patients with Recurrent, Metastatic SCC of the Head and Neck. (AACR). 2001.
View in: PubMed

Haddad R, Morrow AD, Plass C, Held WA. Restriction landmark genomic scanning of mouse liver tumors for gene amplification: overexpression of cyclin A2. Biochem Biophys Res Commun. 2000 Jul 21; 274(1):188-96.
View in: PubMed

Greenberg R, Haddad R, Kashtan H, Kaplan O. The effects of somatostatin and octreotide on experimental and human acute pancreatitis. J Lab Clin Med. 2000 Feb; 135(2):112-21.
View in: PubMed

Schneebaum S, Troitsa A, Avital S, Haddad R, Kashtan H, Gitstein G, Baratz M, Brazovsky E, Papo J, Skornick Y. Identification of lymph node metastases in recurrent colorectal cancer. Recent Results Cancer Res. 2000; 157:281-92.
View in: PubMed

Haddad R, Suntharalingam M, Chen T, Levy S, VanEcho DA. Pretreatment Hemoglobin (Hgb) Is Associated With Response to Chemoradiation Therapy (CRT) in Patients with Advanced, Unresectable Squamous Cell Carcinoma of the Head and Neck (SCCHN). (ASCO Proc)(Poster discussion session). 2000; 19:1646.
View in: PubMed

Kashtan H, Konikoff F, Haddad R, Umansky M, Skornick Y, Halpern Z. [Photodynamic therapy for dysphagia due to esophageal carcinoma]. Harefuah. 1999 Nov 15; 137(10):441-4, 512.
View in: PubMed

Srivastava S, Haddad R, Kleinman G, Manthous CA. Erythema nodosum after smoke inhalation-induced bronchiolitis obliterans organizing pneumonia. Crit Care Med. 1999 Jun; 27(6):1214-6.
View in: PubMed

Greenberg R, Haddad R, Kashtan H, Brazowski E, Graff E, Skornick Y, Kaplan O. Continuous intravenous octreotide treatment for acute experimental pancreatitis. Digestion. 1999 Mar-Apr; 60(2):125-31.
View in: PubMed

Haddad R, Wolf Y, Alagem D, Cohn M, Skornick Y, Kluger Y. Anchoring the diaphragm after blunt trauma. Injury. 1999 Jan; 30(1):57-8.
View in: PubMed

Haddad R, Rapoport AR, Cottler-Fox M, Chen T, Tricot G, Fassas A. Delayed Use of Granulocyte Colony-Stimulating Factor Following Autologous Peripheral Blood Stem Cell Transplantation Does Not Affect Engraftment or Hospital Stay. Blood. 1999; 10(Supp 1):4821.
View in: PubMed

Cohen M, Gat A, Haddad R, Avital S, Even-Sapir E, Skornick Y, Shafir R, Schneebaum S. Single-injection gamma probe-guided sentinel lymph node detection in 40 melanomatous lymphadenectomies. Ann Plast Surg. 1998 Oct; 41(4):397-401.
View in: PubMed

Haddad R, Blumenfeld A, Siegal A, Kaplan O, Cohen M, Skornick Y, Kashtan H. In vitro and in vivo effects of photodynamic therapy on murine malignant melanoma. Ann Surg Oncol. 1998 Apr-May; 5(3):241-7.
View in: PubMed

Avital S, Hitchcock CL, Baratz M, Haddad R, Skornick Y, Schneebaum S. Localization of monoclonal antibody CC49 in colonic metastasis from renal cell carcinoma. Eur J Surg Oncol. 1998 Apr; 24(2):149-51.
View in: PubMed

Haddad R, Held WA. Genomic imprinting and Igf2 influence liver tumorigenesis and loss of heterozygosity in SV40 T antigen transgenic mice. Cancer Res. 1997 Oct 15; 57(20):4615-23.
View in: PubMed

Nagar H, Haddad R. Impact of early orchidopexy on testicular growth. Br J Urol. 1997 Aug; 80(2):334-5.
View in: PubMed

Jacob B, Amoateng-Adjepong Y, Rasakulasuriar S, Manthous CA, Haddad R. Preoperative pulmonary function tests do not predict outcome after coronary artery bypass. Conn Med. 1997 Jun; 61(6):327-32.
View in: PubMed

Wolf Y, Haddad R, Werbin N, Skornick Y, Kaplan O. Endometriosis in abdominal scars: a diagnostic pitfall. Am Surg. 1996 Dec; 62(12):1042-4.
View in: PubMed

Alperovitch R, Haddad R. [Hand burns in children. Retrospective study of 137 cases from 1973-1982 representing 177 hands]. Chir Pediatr. 1984; 25(1):43-7.
View in: PubMed

Research Departments:

Medical Oncology/Solid Tumor Oncology

Support My Research

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Get Directions

Caregiving

Coping with Cancer

COVID-19

Health & Wellness

Nutrition & Diet

Risk & Prevention

Survivorship

Teaching Sheets

Treatments & Procedures

Video
News Releases
4/3/2017
Some head and neck cancer patients benefit from continued checkpoint inhibitor treatment after tumor

Immunotherapy
Head and Neck Cancer

News Releases
6/6/2016
Pembrolizumab elicits significant anti-tumor activity in advanced head and neck cancer patients

Research
Head and Neck Cancer

Top

Find a Doctor